Literature DB >> 62998

Evidence for prevention of borderline leprosy reactions by dapsone.

R S Barnetson, J M Pearson, R J Rees.   

Abstract

68 patients were included in a prospective study of the treatment of borderline leprosy. 34 were treated with dapsone 5 mg daily, and 34 with 50 mg daily. Reversal reactions developed in 11 of those on 5 mg daily and in 3 of those on 50 mg daily. The statistically significant difference between the two treatment groups indicates that, contrary to previous teaching, dapsone given in higher dosage does not predispose patients to reversal reactions and indeed may prevent them.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62998     DOI: 10.1016/s0140-6736(76)91684-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis.

Authors:  D R Swinson; J Zlosnick; L Jackson
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

2.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16

3.  Severe type 1 upgrading leprosy reaction in a renal transplant recipient: a paradoxical manifestation associated with deficiency of antigen-specific regulatory T-cells?

Authors:  Ana Paula Vieira; Maria Angela Bianconcini Trindade; Flávio Jota de Paula; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Francine Brambate Carvalhinho Lemos; Gil Benard
Journal:  BMC Infect Dis       Date:  2017-04-24       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.